Physician profile
Joseph Kim
NPI 1689640625
$3,833.66
in general payments reported to CMS, 2019-2025
22 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $193 · 2021: $571 · 2022: $1,426 · 2023: $513 · 2024: $407 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $884.12 | 2022 | |
| Abbvie INC. | $463.12 | 2019-2025 | |
| Gilead Sciences, INC. | $348.37 | 2019-2024 | |
| Viiv Healthcare Company | $275.48 | 2019-2024 | Dovato, Cabenuva |
| La Jolla Pharmaceutical Company | $241.38 | 2020-2024 | Xacduro |
| Merck Sharp & Dohme LLC | $235.97 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Cipla USA INC. | $213.25 | 2022 | |
| Insmed, INC. | $204.99 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Aurinia Pharma U.S., INC. | $145.57 | 2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $124.96 | 2019 | |
| Paratek Pharmaceuticals, INC. | $115.41 | 2020-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $95.87 | 2019 | |
| Allergan, INC. | $55.60 | 2019 | |
| Melinta Therapeutics, LLC | $52.17 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.42 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $32.84 | 2024 | |
| Ferring Pharmaceuticals INC. | $32.05 | 2024 | Rebyota |
| Shionogi INC | $18.36 | 2025 | Fetroja |
| Janssen Biotech, INC. | $15.72 | 2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.43 | 2022 | |
| Tactile Systems Technology INC | $14.58 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.